HLA-DRB5 Antikörper (AA 43-70)

Produktnummer ABIN2621925

Produktdetails anti-HLA-DRB5 Antikörper

Target: HLA-DRB5 (Major Histocompatibility Complex, Class II, DR beta 5 (HLA-DRB5))

Bindungsspezifität: AA 43-70

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HLA-DRB5 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Spezifität: This HLA-DRB5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 43-70 amino acids from the Central region of human HLA-DRB5.

Aufreinigung: Affinity purified

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Approved: ELISA (1:1000), IHC (1:50 - 1:100), WB (1:100 - 1:500)

Kommentare:

Target Species of Antibody: Human

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: PBS,  pH 7.2, 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Aliquot to avoid repeated freezing and thawing.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: May be stored at 4°C for short-term only. Aliquot to avoid freeze-thaw cycles. Store at -20°C. Aliquots are stable for 1 year.

Details zu HLA-DRB5

Target: HLA-DRB5 (Major Histocompatibility Complex, Class II, DR beta 5 (HLA-DRB5))

Andere Bezeichnung: HLA-DRB5 (HLA-DRB5 Produkte)

Synonyme: HLA-DRB antikoerper, major histocompatibility complex, class II, DR beta 5 antikoerper, HLA-DRB5 antikoerper

Hintergrund: Name/Gene ID: HLA-DRB5

Synonyms: HLA-DRB5, DR-9, DR beta-5, Dw2, HLA-DRB, Human leucocyte antigen DRB5, MHC class II antigen DRB1*9, MHC class II HLA beta chain, MHC HLA-DR-beta chain, Leukocyte antigen class II, DR2-beta-2, DR9, MHC class II antigen DRB5

Gen-ID: 3127

Pathways: T-Zell Rezeptor Signalweg, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints